Since PARPis can synergize with anti-angiogenic agents in ovarian cancer (Le Saux et al, 2021), we examined whether blocking pro-angiogenic VEGFR2 signaling could sensitize PARPi-resistant breast tumors to talazoparib. Here, KDR is linked to ovarian carcinoma.